Ingrid Walker

We are very excited to say that after more than 30 years of research and development, we have received the Swissmedic approval for our new treatment for resistant hypertension in our home country of Switzerland, following the approval in the US and EU last year and the UK earlier this year. We are engaged in discussions with potential partners to make this drug available to patients across Switzerland and Europe. Read more: https://bit.ly/idiamr

722

4 Kommentare

Patient safety is the foundation of our work at Daiichi Sankyo. It goes beyond science and data: it is about making sure that treatments are effective, safe, and supportive for every patient, in every context. At this year’s Daiichi Sankyo Europe GmbH Patient Safety Day, a dedicated panel discussion brought us together with two patient advocates who shed light on topics that matter deeply: fertility, lactation, family well-being, and the need for transparent conversations about future plans. These perspectives remind us that safety must be defined together with patients, not only by protocols. For us at Daiichi Sankyo, patient safety means creating a continuous feedback loop: listening, learning, and applying those learnings across everything we do – from study design to treatment support. This commitment requires teamwork across all functions, and it relies on trust with the patients who share their experiences with us. Every single voice contributes to advancing safety standards and to shaping better care for the future.

139

👋 Welcome to Biopôle, Undae Science SA! 💤 Built on deep sleep expertise, Undae Science is working to transform clinical sleep management and improve population health. Sleep disturbances already cost Switzerland over CHF 10 billion each year, and current diagnostics rely on intrusive, single-night hospital exams that often disrupt natural sleep and delay accurate diagnoses. 💡 Their innovation, Noctae, reimagines the sleep medical station: a user-friendly, contactless over-mattress device that enables multi-night, clinical-grade monitoring in the comfort of home. Powered by proprietary AI and years of cutting-edge research, Noctae delivers accuracy on par with hospital gold standards without the need for overnight stays. 🔎 Learn more about their pioneering approach to sleep health: https://lnkd.in/dAKwmktb

147

4 Kommentare

Quality meets Expertise 2025 | Cardiovascular Diseases 🌍   From Monday, July 28 to Friday, August 1, our latest Quality meets Expertise event took place in Berlin, bringing together healthcare professionals to foster networking and encourage knowledge exchange in the field of cardiovascular diseases.   We were honored to have two keynote speakers:   Univ.-Prof. Dr. Donato Santovito from LMU Klinikum München presented on cardiovascular prevention and patient-tailored therapies, focusing on strategies to manage cardiovascular risk factors effectively.   Dr. Moez J. Mobarek from the Al-Jawad Oncology Center in Baghdad examined the prevention and treatment of cancer-associated thrombosis, emphasizing the importance of preventive measures and providing guidance on the administration of apixaban for Venous Thromboembolism (VTE).   Watch the full Aftermovie on YouTube: https://lnkd.in/dXYBMdmj    #QualityMeetsExpertise #CardiovascularHealth #HealthcareInnovation #Berlin

74

2 Kommentare

Great news from our subsidiary, cecava GmbH: Precision Medicine Online, an established news and analysis portal for precision oncology, has published an in-depth article based on an interview with Saskia Biskup, MD/PhD. It covers the latest developments in individualized peptide therapy for IDH1-mutated gliomas. Based on cecava's recent press release, the article highlights the scientific background, key study results, and the next steps toward a clinical trial. We are delighted about this well-deserved attention and congratulate the entire cecava team! Learn more about cecava's pioneering approach here: https://lnkd.in/eAtAAKVu Read the full article on Precision Medicine Online here (subscription needed): https://lnkd.in/eGuKt4cX

84

2 Kommentare

Specialist knowledge ✔️ Foresight ✔️ And a genuine commitment to quality in healthcare ✔️ We do not develop our solutions on our own - but in close cooperation with leading experts in laboratory medicine worldwide. ✨ One such expert is Jaffar Khiariy, member of our Medical Advisory Board and distinguished laboratory medicine leader from King Faisal Specialist Hospital and Research Centre in Jeddah, Saudi Arabia - an inspiring sparring partner on the path to better solutions in preanalytics. In the new podcast episode, he shares his perspectives on: 🎙 the chances of evolving digital workflows and monitoring capabilities in preanalytics, 🎙 the crucial role of thorough staff training in understanding the science behind procedures 🎙 the balance between technological advancement and compassionate patient care. 🎧 Tune in now and benefit from his experience: https://lnkd.in/d_STQ6_a Image: Quote of Jaffar Khiariy on the importance of a streamlined sample transport monitoring. #DigitalPreanalytics #GreinerBioOneTalks #GreinerBioOne

92

Ypsomed Holding AG (SIX: YPSN) announced that the sale of the Ypsomed Diabetes Care business to TecMed AG, initially announced on 22 April 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.   Walder Wyss advised Ypsomed on the carve-out of the diabetes care business and the sale to TecMed AG. The team was led by Hans-Jakob Diem (Partner, Corporate/M&A) and Dominik Hohler (Partner, Corporate/M&A) and included Letizia Schlegel (Senior Associate, Corporate/M&A), Michael Kissling (Senior Associate, Corporate/M&A), Michael Isler (Partner, IP/Data Protection and Regulatory), Kento Reutimann (Associate, IP/Data Protection), Florian Iten (Associate, Corporate/M&A), Valentin Wiesner (Managing Associate, Finance) and Valentin Freiermuth (Associate, Finance). https://lnkd.in/dg9_VQ-S

56

💡 Quick Minds Episode 9 with PD Dr. Dr. med. Florian Früh,   New plates, new perspectives - here’s what's actually changing. In this fast-paced, 90-second interview, Dr. Florian Früh - the very first surgeon worldwide to use the Y-plate for a complex finger fracture - opens up about his hands-on experience, the benefits he’s seen with the new Medartis hand plate system, and his personal vision for the future of hand surgery.   Get inspired by Dr. Früh’s insights and discover what’s driving the next generation of fracture fixation. Tune in now!   #QuickMinds #HandTrauma #FractureFixation #ImplantInnovation 

94

1 Kommentar